GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Net Change in Cash

Cytophage Technologies (TSXV:CYTO) Net Change in Cash : C$7.25 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Cytophage Technologies's Net Change in Cash for the three months ended in Mar. 2024 was C$5.54 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was C$7.25 Mil.

Cytophage Technologies Net Change in Cash Historical Data

The historical data trend for Cytophage Technologies's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Net Change in Cash Chart

Cytophage Technologies Annual Data
Trend Dec21 Dec22 Dec23
Net Change in Cash
3.22 -0.12 -0.06

Cytophage Technologies Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial 2.36 -0.87 - 1.71 5.54

Cytophage Technologies Net Change in Cash Calculation

Cytophage Technologies's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.195+0.131+0+0
=-0.06

Cytophage Technologies's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-2.108+7.786+-0.142+0
=5.54

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$7.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytophage Technologies Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Net Change in Cash
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.

Cytophage Technologies (TSXV:CYTO) Headlines

From GuruFocus

Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration

By Marketwired • 07-05-2023

Altamira Therapeutics Provides Year-End 2022 Business Update

By Value_Insider Value_Insider • 12-19-2022

Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia

By Marketwired • 07-20-2023

Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

By ACCESSWIRE ACCESSWIRE • 05-24-2023

Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets

By ACCESSWIRE ACCESSWIRE • 06-01-2023

Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal

By ACCESSWIRE ACCESSWIRE • 04-12-2023

Altamira Therapeutics Announces Reverse Stock Split

By Value_Insider Value_Insider • 10-24-2022

Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

By Marketwired • 09-12-2023

Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023

By ACCESSWIRE ACCESSWIRE • 02-07-2023

Altamira Therapeutics' SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model

By sperokesalga sperokesalga • 03-22-2023